Abstracts tagged "autoimmune diseases"

Abstract Number: 1149 • ACR Convergence 2023
Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series
Tessalyn Morrison¹, Taylor Lakusta-Wong¹, Chantal Roy-Hewitson¹, Jeanne Gosselin² and Alana Nevares³, ¹University of Vermont, Burlington, VT, ²University of Vermont Medical Center, Waterbury, VT, ³University of Vermont, Essex Junction, VT
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granuloma formation affecting the lung, lymphatics, heart, skin, eye, kidney, and, in neurosarcoidosis, the nervous…
Abstract Number: 1443 • ACR Convergence 2023
Vasculitis Associations Among Patients with Systemic Lupus Erythematous
Emily Cosentino¹, Mia Blanchard², Diane L. Kamen¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Claremont Graduate University, Claremont, CA
Background/Purpose: Vasculitis is rare manifestation of systemic lupus erythematous (SLE) that often leads to increased morbidity and mortality. Vasculitis prevalence in SLE patients have ranged…
Abstract Number: 1657 • ACR Convergence 2023
Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution
Gabrielle Rabadam¹, Camilla Wibrand², Emily Flynn¹, George Hartoularos¹, Yang Sun¹, Susan Kim³, Chun Jimmie Ye¹, Zev Gartner¹, Marina Sirota⁴ and Jessica Neely¹, ¹University of California San Francisco, San Francisco, CA, ²Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, ³UCSF Benioff Children's Hospital, San Francisco, CA, ⁴Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare multisystem autoimmune condition that involves complex immune responses in both innate and adaptive compartments. Currently, we have a…
Abstract Number: 1809 • ACR Convergence 2023
Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases
Zhu Chen¹, nan xiang¹, Qian Wang¹, Yuwei Li¹, Huizhi Jin¹, Guosheng Wang¹, Xiaomei Li², Tengchuan Jin¹ and Wei Bao¹, ¹University of Science and Technology of China, Hefei, China, ²University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China
Background/Purpose: The surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron infections has affected most Chinese residents at the end of 2022, including…
Abstract Number: 1945 • ACR Convergence 2023
Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals
Arturo Llobell¹, Inigo Gonzalez-Mazon², carmen secada³, Adrian Martin-Gutierrez³, Almudena García-Castaño³, Enrique Gallardo⁴, Soledad Retamozo⁵, Antonio Gomez-Centeno⁶, Luis Fernandez-Morales⁴, Jordi Gratacos Masmitja⁷ and Ricardo Blanco⁸, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Parc Taulí University Hospital, Sabadell, Spain, ⁵Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain, ⁶Parc Taulí Hospital Universitari, Sabadell, Spain, ⁷University Hospital Parc Taulí, Sabadell, Spain, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Myositis is a rare inflammatory complication associated with immune related adverse events (irAE) of immune checkpoints inhibition (ICI) immunotherapy1. It is characterized by musculoskeletal…
Abstract Number: 2168 • ACR Convergence 2023
The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis
Gilad Halpert¹, Ori Moskovitch¹, Adi Anaki², Tal Caller¹, Omer Gendelman¹, Abdulla watad¹, Ruty Mehrian-Shai¹, Rachella Popovtzer², Boris Guilbord¹, Ori Segal¹ and Howard AMITAL¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Bar Ilan University, Ramat Gan, Israel
Background/Purpose: The use of biological treatment in patients with rheumatoid arthritis (RA) can induce non-specific immune suppression, which might result in higher rates of infections.…
Abstract Number: 2466 • ACR Convergence 2023
Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein
Eveline Van Gompel¹, Ragnhild Stålesen², Caroline Grönwall², Annika van Vollenhoven², Lena Israelsson², Ingrid Lundberg³, Vivianne Malmström², Karine Chemin⁴ and Vijay Joshua², ¹Karolinska Institutet - KU Leuven, Leuven, Belgium, ²Karolinska Institutet, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The strong clinical association between the anti-MDA5 autoantibodies and the development of severe lung disease in patients with dermatomyositis (DM) suggests an active role…
Abstract Number: PP13 • ACR Convergence 2023
My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me
Lisa Rubenstein, Sjögren's Foundation, Los Angeles, CA

Background/Purpose: Being diagnosed with Sjögren’s has been a life changing event for me.I was diagnosed in 2013 after suffering from various odd ailments. Ultimately, extreme…
Abstract Number: 0033 • ACR Convergence 2023
A Novel Transcriptome-Based Machine Learning Pipeline Predicts Phenotypes of Lupus Patients
Emily Leventhal¹, Andrea Daamen¹, Amrie Grammer² and Peter Lipsky², ¹AMPEL BioSolutions, LLC, and The RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gene expression analysis coupled with machine learning (ML) holds the promise of identifying subsets of patients with heterogeneous diseases, such as systemic lupus erythematosus…
Abstract Number: 0098 • ACR Convergence 2023
Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”
Yasaman Ahmadzadeh¹, Larry Magder², Zeynep Ozge Ozdemir³, Danieli Andrade⁴, Megan R.W. Barber⁵, Maria Tektonidou⁶, Savino Sciascia⁷, Vittorio Pengo⁸, Ariadna Anunciación-Llunell⁹, Guillermo Ruiz-Irastorza¹⁰, Mª Angeles Aguirre¹¹, Michael Belmont¹², Kello Nina¹³, Paul R. Fortin¹⁴, Denis WAHL¹⁵, Maria Gerosa¹⁶, Guilherme De Jesús¹⁷, Zhuoli Zhang¹⁸, Tatsuya Atsuma¹⁹, Maria Efthymiou²⁰, D. Ware Branch²¹, Angela Tincani²², Esther Rodriguez almaraz²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁸, Guillermo Pons-Estel²⁹, Rohan Willis³⁰, Ali Duarte-Garcia³¹, Maria Laura Bertolaccini³², Hannah Cohen³³, Michelle Petri³⁴, Doruk Erkan³⁵ and On Behalf Of APS ACTION³⁶, ¹Roger Williams Medical Center, Providence, RI, ²University of Maryland, Baltimore, MD, ³Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴University of São Paulo, São Paulo, Brazil, ⁵University of Calgary, Calgary, AB, Canada, ⁶Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁷University of Turin, Torino, Italy, ⁸Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁹VHIR Vall d'Hebron Institut de Investigación, Barcelona, Spain, ¹⁰Hospital Universitario Cruces, Barakaldo, Spain, ¹¹Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ¹²New York University Langone Medical Center, New York, NY, ¹³Northwell Health, Brooklyn, NY, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁵University of Lorraine, Nancy, France, ¹⁶University of Milan, Milano, Italy, ¹⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁸Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁹Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ²⁰University College London, London, United Kingdom, ²¹University of Utah, Salt Lake City, UT, ²²Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, ²³Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷Rijin Hospital, Shanghai, China, ²⁸University of Michigan, Ann Arbor, MI, ²⁹CREAR, Rosario, Argentina, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹Mayo Clinic, Rochester, MN, ³²King's College London, London, United Kingdom, ³³Haemostasis Research Unit, Department of Hematology, University College London, London, United Kingdom, ³⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ³⁵Hospital for Special Surgery, New York, NY, ³⁶on behalf of APS ACTION, New York, NY
Background/Purpose: APS ACTION "Registry" was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 0222 • ACR Convergence 2023
Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab
Pei-hsinq Lai¹, Ting-wei Chang², Shih-hsun Lan², Chiao-Feng Cheng², Cheng-Hsun Lu² and Song-Chou Hsieh², ¹Taipei City Hospital, Zhongxiao Branch, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Rituximab (RTX) is widely used in immune mediated inflammatory disease (IMID) patients refractory to conventional treatment. Previous studies have indicated that RTX in IMID…
Abstract Number: 0437 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², K Wysham³, Jean liew⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
Abstract Number: 0595 • ACR Convergence 2023
Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Gelareh Atefi⁶, Gary Bryant⁶, Micki Hultquist⁷, Raj Tummala⁷, Gabriel Abreu⁸, Catharina Lindholm⁸ and Hussein Al-Mossawi⁹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In patients with SLE, nephritis is present in 50%–60% during the first 10 years of disease.1 Renal involvement is associated with poor clinical outcomes…
Abstract Number: 0888 • ACR Convergence 2023
Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model
Helene ASNAGLI¹, Simon TESSIER¹, Martyn FOSTER², Sofie DENIES³, Eef HOEBEN⁴, Joël CROUZET¹ and Annegret VAN DER AA¹, ¹Ermium Therapeutics, Paris, France, ²Experimental Pathology Consultancy, Benfleet, United Kingdom, ³SD Analytics, Bellem, Belgium, ⁴2-Bridge, Zoersel, Belgium
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. Type 1…
Abstract Number: 1053 • ACR Convergence 2023
Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease
Denis Krutko¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵, Grant Cannon⁶ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Data on Immune Checkpoint inhibitor (ICI) use in patients with previously diagnosed inflammatory muscle disease (IMD) is limited as these patients were excluded from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].